| ABSTRACT Objective::To observe the clinical efficacy and safety of the chemotherapy of multidrug-resistant tuberculosis (MDR-TB) with moxifloxacin combined with anti tuberculosis drugs. Methods:84 MDR-TB patients were randomly divided into two groups. The treatment group (n=42) were treated with moxifloxacin (M) joint pasiniazid (D), rifapentini（L）, pyrazinamide（Ｚ）and ethambutol(E), and the controlled group (n=42), treated with levofloxacin (V) joint D, L, Z, E for a course of 18 months, respectively. Their phlegm germ feminine changed incidence rate, clinical efficacy and adverse reactions in different periods were observed and compared.Results:At the end of the treatment,the sputum negative conversion rate (90.5%) and cavity closure rate (58.6%) were significantly higher in the treatment group than those (73.8%, 32.1%) in the controlled group(P<0.05). The incidence rates of clinical adverse reactions in the treatment group and controlled group were 33.3% and 31%, respectively. There were no statistical differences in the two groups(P>0.05).Conclusion:Moxifloxacin combined with anti tuberculosis drugs chemotherapy in the treatment of MDR-TB could accelerate the sputum negative conversion and cavity closure with lower adverse reactions, and its clinical curative effect was distinct. |
